Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsJohnson & Johnson's fiscal 2025 sales rose about 6% to $94.2 billion, and its net income includes a roughly $7 billion reversal of its talc reserve.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.